Economic impact of diabetes
• Type 1 diabetes is particularly costly in terms of mortality in poor countries, where many children die because access to life-saving insulin is not subsidised by governments and is often not available at any price. A person requiring insulin for survival in Zambia will live an average of 11 years; a person in Mali can expect to live 30 months; in Mozambique a person requiring insulin will be dead within 12 months.
Sources:
2. WHO (from IDF Diabetes Atlas, 2003)
http://www.depsyl.com/
http://back2basicnutrition.com/
http://bionutritionalresearch.olhblogspace.com
Showing posts with label Cost of Diabetes. Show all posts
Showing posts with label Cost of Diabetes. Show all posts
Friday, January 14, 2011
Sunday, January 2, 2011
Economic impact of Diabetes #2
A relatively simple formula was used to derive the country estimates in this report. The accuracy of these estimates is subject to how well assumptions used in the formula fit the situation of each individual country. The estimated per capita expenditure on diabetes was compared with independent estimates obtained from industrialized countries where direct studies of diabetes costs have been conducted. The IDF approach appears to yield a reasonably accurate estimate. In general, these estimates are less accurate for developing countries than they are for developed countries because of poor quality data in the developing countries, underlining the need for well-designed health economic studies to understand the true impact of diabetes.
Besides the health expenditures, other measurements have also been used to asses the economic impact of diabetes. Several of such measures were described in the Diabetes Atlas, third edition. The main conclusions reached by using these measures include the following. First, diabetes also imposes a large financial burden on people with diabetes and their families.
The size of this burden depends on their economic status and the social insurance policies of the countries in which they live. Individuals with diabetes and their families in developing countries pay a larger share of the expenditure because of the poorer organized systems of medical care insurance and/or lack of governmental provision of medical services. In Latin America, families pay 40-60% of expenditures for medical care from their own pockets. In the poorest countries, people with diabetes and their families bear almost the whole cost of whatever medical care they can afford. In India, for example, the poorest persons with diabetes spend an average of 25% of their total income on healthcare.
Second, at the societal level, diabetes leads to loss in productivity and economic growth. The American Diabetes Association estimated that the US economy lost USD $58 billion, equivalent to about an half of the direct health care expenditure on diabetes in 2007, as a result of lost earnings due to lost work days, restricted activity days, lower productivity at work, mortality and permanent disability caused by diabetes. Such losses are perhaps relatively larger in poorer countries because premature death due to diabetes occurs at much younger ages. The World Health Organization (WHO) predicts net losses in national income from diabetes and cardiovascular disease of ID557.7 billion in China, ID303.2 billion in the Russian Federation, ID336.6 billion in India, ID49.2 billion in Brazil and ID2.5 billion in Tanzania (2005 ID), between 2005 and 2015.
Finally, the largest economic burden caused by diabetes is the monetary value associated with disability and loss of life as a result of the disease itself and its related complications, including heart, kidney, eye and foot disease. Economists have used different methods to value disability and loss of life associated with diseases and the most appropriate method is still under debate. No matter what method is used, it is very likely the economic burden that is
measured by the monetary value associated with this disability and loss of life would be far larger than the estimated economic burden using measures described above.
Fortunately, the economic burden of diabetes can be reduced by implementing many inexpensive, easy-to-use interventions, and most of the interventions are cost-effective or cost-saving, even in the poorest countries. Tragically, these interventions are not widely used in poor and middle income countries. More resources should be invested to deliver these cost effective interventions, in particular to those in the developing countries where the great
majority of persons with diabetes live.
To read complete report, Click on LINK Below:
http://blogimages.bloggen.be/diabetescheck/attach/35597.pdf
www.DEPSYL.com
http://back2basicnutrition.com
http://bionutritionalresearch.olhblogspace.com
Besides the health expenditures, other measurements have also been used to asses the economic impact of diabetes. Several of such measures were described in the Diabetes Atlas, third edition. The main conclusions reached by using these measures include the following. First, diabetes also imposes a large financial burden on people with diabetes and their families.
The size of this burden depends on their economic status and the social insurance policies of the countries in which they live. Individuals with diabetes and their families in developing countries pay a larger share of the expenditure because of the poorer organized systems of medical care insurance and/or lack of governmental provision of medical services. In Latin America, families pay 40-60% of expenditures for medical care from their own pockets. In the poorest countries, people with diabetes and their families bear almost the whole cost of whatever medical care they can afford. In India, for example, the poorest persons with diabetes spend an average of 25% of their total income on healthcare.
Second, at the societal level, diabetes leads to loss in productivity and economic growth. The American Diabetes Association estimated that the US economy lost USD $58 billion, equivalent to about an half of the direct health care expenditure on diabetes in 2007, as a result of lost earnings due to lost work days, restricted activity days, lower productivity at work, mortality and permanent disability caused by diabetes. Such losses are perhaps relatively larger in poorer countries because premature death due to diabetes occurs at much younger ages. The World Health Organization (WHO) predicts net losses in national income from diabetes and cardiovascular disease of ID557.7 billion in China, ID303.2 billion in the Russian Federation, ID336.6 billion in India, ID49.2 billion in Brazil and ID2.5 billion in Tanzania (2005 ID), between 2005 and 2015.
Finally, the largest economic burden caused by diabetes is the monetary value associated with disability and loss of life as a result of the disease itself and its related complications, including heart, kidney, eye and foot disease. Economists have used different methods to value disability and loss of life associated with diseases and the most appropriate method is still under debate. No matter what method is used, it is very likely the economic burden that is
measured by the monetary value associated with this disability and loss of life would be far larger than the estimated economic burden using measures described above.
Fortunately, the economic burden of diabetes can be reduced by implementing many inexpensive, easy-to-use interventions, and most of the interventions are cost-effective or cost-saving, even in the poorest countries. Tragically, these interventions are not widely used in poor and middle income countries. More resources should be invested to deliver these cost effective interventions, in particular to those in the developing countries where the great
majority of persons with diabetes live.
To read complete report, Click on LINK Below:
http://blogimages.bloggen.be/diabetescheck/attach/35597.pdf
www.DEPSYL.com
http://back2basicnutrition.com
http://bionutritionalresearch.olhblogspace.com
Tuesday, October 5, 2010
Cost Of Diabetes Non-Adherence $11,000 Yearly Per Patient
Tuesday, May 12, 2009
There are important variations in the reported costs of diabetes non-adherence which are due to methodological differences among studies. Therefore, decision makers need to identify those sources of variation, and base their decision only on high quality studies.
The objective was to review and analyze carefully all published studies related to costs of diabetic patients who do not adhere to medications and identify sources of differences among studies.
Two hundred nineteen studies were identified with important differences in the estimated costs. For example, if patients do not take the medicine as prescribed for 5 years, this will increase the average total costs from $4,000 to more than $15,000, depending on the study. The differences in those estimations are due to characteristics of patients included, data sources for costs, time of follow-up and methods used for analysis.
Costs of not taking medications as prescribed have an impact on the US economy increasing the costs up to $100 billion per year. In addition, poor adherence to antidiabetic medications might explain why 43% of patients with diabetes mellitus do not reach adequate glycemic control.
This is a true teamwork effort, Dr. Salas said, that has been supported by the ISPOR Special Interest Initiative that provided a forum for information exchange among interested members. This topic is especially important because diabetes is a chronic disease where it is important to maintain adequate drug levels in the body to obtain an effect, which might be translated in reduction of morbi-mortality.
Source: Diabetes In Control: The article appeared in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care resources wisely, fairly, and efficiently.
http://bionutritionalresearch.olhblogspace.com/
http://back2basicnutrition.com/
There are important variations in the reported costs of diabetes non-adherence which are due to methodological differences among studies. Therefore, decision makers need to identify those sources of variation, and base their decision only on high quality studies.
The objective was to review and analyze carefully all published studies related to costs of diabetic patients who do not adhere to medications and identify sources of differences among studies.
Two hundred nineteen studies were identified with important differences in the estimated costs. For example, if patients do not take the medicine as prescribed for 5 years, this will increase the average total costs from $4,000 to more than $15,000, depending on the study. The differences in those estimations are due to characteristics of patients included, data sources for costs, time of follow-up and methods used for analysis.
Costs of not taking medications as prescribed have an impact on the US economy increasing the costs up to $100 billion per year. In addition, poor adherence to antidiabetic medications might explain why 43% of patients with diabetes mellitus do not reach adequate glycemic control.
This is a true teamwork effort, Dr. Salas said, that has been supported by the ISPOR Special Interest Initiative that provided a forum for information exchange among interested members. This topic is especially important because diabetes is a chronic disease where it is important to maintain adequate drug levels in the body to obtain an effect, which might be translated in reduction of morbi-mortality.
Source: Diabetes In Control: The article appeared in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research. ISPOR is a nonprofit, international organization that strives to translate pharmacoeconomics and outcomes research into practice to ensure that society allocates scarce health care resources wisely, fairly, and efficiently.
http://bionutritionalresearch.olhblogspace.com/
http://back2basicnutrition.com/
Subscribe to:
Posts (Atom)
